SEER Inquiry System - Question 20041064 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 11/27/2024 4:49 PM

Question 20041064

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

2004 SEER Manual, 127, C-476

Question:

CS Tumor Size/CS Extension/CS TS/Ext-Eval--Breast: How do you code these fields when the tumor size and extension differ pre and post treatment with neoadjuvant Arimidex? See Discussion.

Discussion:

Clinically on PE 3 cm mass attached to skin with dimpling and erythema overlying the mass. Ultrasound: 2-3 cm breast mass with overlying skin thickened by US evaluation, suggesting dermal invasion. Neoadjuvant Arimidex followed by MRM. Path: 4.5 cm ductal carcinoma (no DCIS), no invasion of skin.

Answer:

This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.Record the larger tumor size and the farthest extension documented.

Code CS Tumor Size/Extension Evaluation to 6 [Surgical resection performed, WITH pre-surgical systemic treatment...; tumor size/extension based on pathologic evidence].

Code CS Tumor Size for the example to 045 [4.5 cm].

Code CS Extension to 20 [Local skin involvement ...] based on clinical description provided.

Cancer Site Category:

Breast

Data Item Category:

N/A

Other Category:

N/A

Year:

2004